Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma
Educational Webinar with Dr. Matthias Orth from University of Heidelberg at University Hospital Mannheim.
Educational Workshop with Dr. Ilaria Ferrarotti
Educational Workshop with Pr Giovanni Palladini
Educational Workshop with Dr Matthias Orth